Waxman/Hatch Reforms Still Allow Multiple 30-Month Stays, PhRMA Says

FDA should "clarify" that Waxman/Hatch reforms included in the Medicare law still allow for more than one 30-month stay on ANDA approval in some cases, the Pharmaceutical Research & Manufacturers of America said in comments submitted to FDA's generic drugs docket